From Fred Alger Management: Cabaletta是一家临床阶段的生物技术公司,专注于发现和开发自身免疫性疾病的靶向细胞疗法。
该公司的主要候选药物 CABA-201 是一种治疗狼疮和肌炎的细胞疗法,美国食品和药物管理局已接受 CABA-201 的新药申请,为 1/2 期的初步读数...查看全文
产业链观察2022-10-11 19:19
药闻▶2022年10月11日,中国南京和上海,美国宾夕法尼亚州费城和加利福尼亚州圣何塞,——驯鹿生物(“IASO Bio”),一家处于临床阶段、致力于细胞创新药物开发的生物制药公司与$Cabaletta Bio(CABA)$ ,一家致力于针对自身免疫性疾病患者开发和商业化的首个靶向细胞疗法的临床阶段...查看全文
$Cabaletta Bio(CABA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-23-049005 Size: 10 KB 网页链接
$Cabaletta Bio(CABA)$ 144 Report of proposed sale of securities Accession Number: 0001950047-23-004172 Act: 33 Size: 6 KB 网页链接
$Cabaletta Bio(CABA)$ 8-K Current report, items 7.01 and 9.01 Accession Number: 0001193125-23-228144 Act: 34 Size: 4 MB 网页链接
$Cabaletta Bio(CABA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-23-043920 Size: 10 KB 网页链接
$Cabaletta Bio(CABA)$ 8-K Current report, items 7.01, 8.01, and 9.01 Accession Number: 0001193125-23-217481 Act: 34 Size: 180 KB 网页链接
$Cabaletta Bio(CABA)$ 144 Report of proposed sale of securities Accession Number: 0001950047-23-003296 Act: 33 Size: 6 KB 网页链接
$Cabaletta Bio(CABA)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001193125-23-208133 Act: 33 Size: 57 KB 网页链接
$Cabaletta Bio(CABA)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0000950170-23-040966 Act: 34 Size: 9 MB 网页链接
$Cabaletta Bio(CABA)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001193125-23-208095 Act: 34 Size: 216 KB 网页链接
$Cabaletta Bio(CABA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-23-033944 Size: 5 KB 网页链接